Quarterly results for Morepen Laboratories Ltd
Morepen Laboratories Limited – Q2 & H1 FY26 Results Summary
Announcement Date: 14 November 2025
Key Financial Metrics (Consolidated):
- Revenue: Rs. 41,157.58 lakhs in Q2 FY26, down 3.2% QoQ and 6.0% YoY; H1 FY26 revenue at Rs. 83,681.46 lakhs vs Rs. 89,294.18 lakhs in H1 FY25.
- EBITDA Proxy (PBT before exceptional items): Rs. 1,986.95 lakhs in Q2 FY26 vs Rs. 1,551.64 lakhs in Q1 FY26 and Rs. 4,602.27 lakhs in Q2 FY25.
- Exceptional Items: Rs. 2,582.54 lakhs gain in Q2 FY26 from sale of equity shares in former subsidiary Dr. Morepen Limited.
- Profit Before Tax: Rs. 4,569.49 lakhs in Q2 FY26.
- Net Profit after Minority Interest: Rs. 4,087.46 lakhs in Q2 FY26, up QoQ from Rs. 1,074.83 lakhs but down YoY from Rs. 3,484.86 lakhs.
- EPS (Basic & Diluted): Rs. 0.75 in Q2 FY26 vs Rs. 0.20 in Q1 FY26 and Rs. 0.65 in Q2 FY25.
- Net Profit Margin (Q2 FY26): Approx. 9.9% (Net Profit / Revenue).
Standalone Financials:
- Revenue: Rs. 36,952.63 lakhs in Q2 FY26, down QoQ but slightly up YoY.
- Net Profit: Rs. 1,437.73 lakhs in Q2 FY26, up QoQ but down YoY.
- EPS: Rs. 0.26 in Q2 FY26.
Balance Sheet Highlights (as of 30 Sept 2025, Consolidated):
- Total Assets: Rs. 1,73,614 lakhs.
- Equity: Rs. 1,19,623 lakhs.
- Current Liabilities: Rs. 46,440 lakhs, with a notable increase in short-term borrowings by Rs. 6,689 lakhs in H1 FY26.
- Cash & Cash Equivalents: Rs. 3,319 lakhs.
Capex & Investments:
- H1 FY26 Capex: Rs. 4,053 lakhs (PPE) and Rs. 5,144 lakhs (Intangibles) consolidated.
- Proceeds from sale of shares in Dr. Morepen Limited: Rs. 3,065 lakhs in H1 FY26.
- Net inflow from investments: Rs. 3,700 lakhs consolidated in H1 FY26.
Management Commentary & Key Developments:
- Dr. Morepen Limited ceased to be a subsidiary from 31 July 2025 due to shareholding reduction to 19.96%; accounted as an investment going forward.
- Exceptional gain recognized from sale of equity shares in Dr. Morepen Limited.
- No impairment on residual investment expected.
- Final dividend of Rs. 0.20 per equity share paid in September 2025.
- Interim results prepared as per Ind AS 34; no audit qualifications reported.
Cash Flow:
- Consolidated operating cash flow positive at Rs. 1,586 lakhs in H1 FY26; standalone operating cash flow negative at Rs. (354) lakhs.
- Financing activities provided Rs. 4,441 lakhs consolidated to support capex and working capital.
Outlook:
- No explicit guidance provided.
- Management notes impact of deconsolidation of Dr. Morepen Limited on future results.
This summary captures the key financial and operational highlights for Morepen Laboratories Limited for Q2 and H1 FY26, reflecting the impact of subsidiary deconsolidation, ongoing capex, and financial performance trends.